Last reviewed · How we verify
FluarixTM
Fluarix is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.
Fluarix is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children ≥6 months of age.
At a glance
| Generic name | FluarixTM |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Fluarix contains inactivated (killed) influenza virus antigens from three or four circulating seasonal flu strains. When administered, it triggers the adaptive immune response, prompting B cells to produce neutralizing antibodies and T cells to develop cellular immunity against the included viral strains. This immune memory protects against infection or reduces disease severity upon exposure to matching influenza viruses.
Approved indications
- Seasonal influenza prevention in adults and children ≥6 months of age
Common side effects
- Injection site soreness, redness, or swelling
- Myalgia (muscle aches)
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
- Study to Evaluate an Influenza Vaccine Candidate (PHASE2)
- Study to Monitor the Safety and Reactogenicity of Fluarix™ in Korean Subjects Aged > 6 Months of Age. (PHASE4)
- Safety and Immunogenicity Study of GSK Biologicals' Seasonal Influenza Candidate Vaccine (GSK2321138A) (PHASE3)
- A Study for Evaluation of Immunogenicity and Reactogenicity of FluarixTM / Influsplit SSW® 2009/2010 in Adults (PHASE3)
- Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline Biologicals' Influenza Vaccine in Elderly People (PHASE3)
- Immunogenicity and Safety Study of GSK Biologicals' Influenza Vaccine When Administered in Children (PHASE3)
- Immunogenicity and Safety Study of FluarixTM Vaccine in Children Who Have Previously Been Vaccinated With PandemrixTM (PHASE4)
- Study to Evaluate the Immunogenicity and Safety of a Second Vaccination With the Adjuvanted Influenza Vaccine Candidate (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- FluarixTM CI brief — competitive landscape report
- FluarixTM updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI